Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) EBITDA Margin: 2022-2025

Historic EBITDA Margin for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to 1,864.43%.

  • Centessa Pharmaceuticals' EBITDA Margin rose 21930.00% to 1,864.43% in Q3 2025 from the same period last year, while for Sep 2025 it was -3,589.64%, marking a year-over-year decrease of 516069.00%. This contributed to the annual value of 2,309.58% for FY2024, which is 447061.00% up from last year.
  • As of Q3 2025, Centessa Pharmaceuticals' EBITDA Margin stood at 1,864.43%, which was up 5.79% from 1,762.38% recorded in Q2 2025.
  • Over the past 5 years, Centessa Pharmaceuticals' EBITDA Margin peaked at 4,405.45% during Q4 2024, and registered a low of -188.49% during Q1 2025.
  • For the 3-year period, Centessa Pharmaceuticals' EBITDA Margin averaged around 1,703.15%, with its median value being 1,645.13% (2024).
  • Per our database at Business Quant, Centessa Pharmaceuticals' EBITDA Margin tumbled by 302,704bps in 2023 and then skyrocketed by 299,988bps in 2024.
  • Over the past 4 years, Centessa Pharmaceuticals' EBITDA Margin (Quarterly) stood at 1,950.75% in 2022, then tumbled by 54,518bps to 1,405.56% in 2023, then surged by 299,988bps to 4,405.45% in 2024, then skyrocketed by 21,930bps to 1,864.43% in 2025.
  • Its last three reported values are 1,864.43% in Q3 2025, 1,762.38% for Q2 2025, and -188.49% during Q1 2025.